Peptides radiolabeled with Re-186/188 and Tc-99m as potential diagnostic and therapeutic agents

E. GARCÍA-GARAYOA; R. SCHIBLI; P.A. SCHUBIGER

doi:10.1016/S1001-8042(07)60026-8

Your Location：

Home >

Browse articles >

Peptides radiolabeled with Re-186/188 and Tc-99m as potential diagnostic and therapeutic agents

RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICINE | Updated：2021-01-29

- Peptides radiolabeled with Re-186/188 and Tc-99m as potential diagnostic and therapeutic agents
- Nuclear Science and Techniques Vol. 18, Issue 2, (2007)
- Affiliations：
  
  1.Center for Radiopharmaceutical Science of the ETH Zurich-Paul Scherrer Institut-University Hospital Zurich, CH-5232, Villigen PSI, Switzerland;
  2.Department of Chemistry and Applied Biosciences ETH Zurich, 8093 Zurich, Switzerland
- Author bio：
  
  Correspondig author. E-mail: august.schubiger@pharma.ethz.ch
- Funds：
- DOI：10.1016/S1001-8042(07)60026-8
  CLC：
Scan for full text
Cite this article
E. GARCÍA-GARAYOA, R. SCHIBLI, P.A. SCHUBIGER. Peptides radiolabeled with Re-186/188 and Tc-99m as potential diagnostic and therapeutic agents. [J]. Nuclear Science and Techniques 18(2):88-100(2007)
DOI：

E. GARCÍA-GARAYOA, R. SCHIBLI, P.A. SCHUBIGER. Peptides radiolabeled with Re-186/188 and Tc-99m as potential diagnostic and therapeutic agents. [J]. Nuclear Science and Techniques 18(2):88-100(2007) DOI： 10.1016/S1001-8042(07)60026-8.

摘要

Abstract

Small peptide-based compounds have attracted an enormous interest as carrier molecules to selectively deliver radionuclides to target tissues, sparing critical normal organs. When looking for "matched pairs" of radionuclides, suitable for radiolabeling of peptides for diagnosis and therapy, technetium and rhenium represent an almost ideal constellation. The important role of technetium-99m and Re-186/188 is based on the decay characteristics, suitable for tumor diagnosis and therapy. Tc-99m and Re-188 are readily available by either a ,99,Mo/,99m,Tc or the ,188,W/,188,Re radionuclide generator system. Furthermore, technetium and rhenium are chemically related and share structural as well as reactive similarities, which prompt an attractive "matched-pair" situation. This article shows an overview of ,99m,Tc- and ,186/188,Re-radiolabeled peptides that have been tested for their potential use as imaging and therapeutic agents in oncological diseases.

关键词

Keywords

Radiolabeled peptidesImagingTherapyOncologyTechnetium-99mRhenium-186/188

references

Liu S, Edwards D S. Chem Revs, 1999, 99: 2235-2268.

Shigeta N, Matsuoka H, Osa A, et al. Journal of Radioanalytical and Nuclear Chemistry-Articles, 1996, 205: 85-92.

Ehrhardt G J, Blumer M E, Su F M, et al. Applied Radiation and Isotopes, 1997, 48: 1-4.

Lapi S, Ressler J J, Cox M E, et al. Technetium and rhenium and other metals in chemistry and nuclear medicine 7. Padua: SGE Editoriali, 2006: 593-596.

Hohn A, Hirzel W, Schibli R. Technetium and rhenium and other metals in chemistry and nuclear medicine 7. Padua, 2006: 609-610.

Knapp F F, Mirzadeh S, Beets A L, et al. Technetium and rhenium in chemistry and nuclear medicine 4. Padua: SGE Editoriali, 1995: 319-324.

Liu G Z, Zhang S R, He J, et al. Bioconjugate Chem, 2002, 13: 893-897.

Liu G Z, Dou S P, He J, et al. Applied Radiation and Isotopes, 2006, 64: 971-978.

Thakur M L, Kolan H, Li J, et al. Nucl Med Biol, 1997, 24: 105-113.

Okarvi S M. Medicinal Research Reviews, 2004, 24: 357-397.

Liu S, Edwards D S, Looby R J, et al. Bioconjugate Chem, 1996, 7: 63-71.

Maina T, Nock B, Nikolopoulou A, et al. Eur J Nucl Med Mol Imaging, 2002, 29: 742-753.

Maina T, Stolz B, Albert R, et al. Eur J Nucl Med, 1994, 21: 437-444.

Harris T D, Sworin M, Williams N, et al. Bioconjugate Chem, 1999, 10: 808-814.

Edwards D S, Liu S, Barrett J A, et al. Bioconjugate Chem, 1997, 8: 146-154.

Kothari K K, Gali H, Prabhu K R, et al. Nucl Med Biol, 2002, 29: 83-89.

Gali H, Hoffman T J, Sieckman G L, et al. Bioconjugate Chem, 2001, 12: 354-363.

Karra S R, Schibli R, Gali H, et al. Bioconjugate Chem, 1999, 10: 254-260.

Alberto R, Schibli R, Egli A, et al. J Organomet. Chem, 1995, 493: 119-127.

Alberto R, Schibli R, Egli A, et al. J Am Chem Soc, 1998, 120: 7987-7988.

Alberto R, Schibli R, Schubiger A P, et al. J Am Chem Soc, 1999, 121: 6076-6077.

Egli A, Hegetschweiler K, Alberto R, et al. Organometallics, 1997, 16: 1833-1840.

Schibli R, Schwarzbach R, Alberto R, et al. Bioconjugate Chem, 2002, 13: 750-756.

Park S H, Seifert S, Pietzsch H J. Bioconjugate Chem, 2006, 17: 223-225.

Miao Y B, Owen N K, Whitener D, et al. Int J Cancer, 2002, 101: 480-487.

Boerman O C, Oyen W J G, Corstens F H M. Semin Nucl Med, 2000, 30: 195-208.

Merrifield B. Solid-Phase Peptide Synthesis. 1997: 3-13.

JrWentworth P. Trends Biotechnol, 1999, 17: 448-452.

Lambert B, Cybulla M, Weiner S M, et al. Radiation Research, 2004, 161: 607-611.

Krenning E P, Kwekkeboom D J, Bakker W H, et al. Eur J Nucl Med, 1993, 20: 716-731.

Virgolini I, Raderer M, Kurtaran A, et al. New England Journal of Medicine, 1994, 331: 1116-1121.

Kwekkeboom D J, Krenning E P. Semin Nucl Med, 2002, 32: 84-91.

Menda Y, Kahn D. Semin Nucl Med, 2002, 32: 92-96.

Blum J, Handmaker H, Lister-James J, et al. Chest, 2000, 117: 1232-1238.

Decristoforo C, Mather S J, Cholewinski W, et al. Eur J Nucl Med, 2000, 27: 1318-1325.

Bangard M, Behe M, Guhlke S, et al. Eur J Nucl Med, 2000, 27: 628-637.

Marmion M E, Alberto R, Bugaj J, et al. J Labelled Compd Radiopharm, 1999, 42: S231-S233.

Schibli R, Schubiger A P. Eur J Nucl Med, 2002, 29: 1529-1541.

Wester H J. Cancer Biotherapy and Radiopharmaceuticals, 2003, 18: 277-277.

Wester H J, Schottelius M, Schwaiger M. J Nucl Med, 2001, 42: 115P-115P.

Pearson D A, Lister-James J, McBride W J, et al. J Med Chem, 1996, 39: 1372-1382.

Zinn K R, Buchsbaum D J, Chaudhuri T R, et al. J Nucl Med, 2000, 41: 887-895.

Zamora P O, Bender H, Gulhke S, et al. Anticancer Res, 1997, 17: 1803-1808.

Bugaj J E, Bickel E M, Azure M T, et al. J Nucl Med, 2002, 43: 123P-123P.

Van de Wiele C, Dumont F, Van den Broecke R, et al. Eur J Nucl Med, 2000, 27: 1694-1699.

Nock B, Nikolopoulou A, Chiotellis E, et al. Eur J Nucl Med Mol Imaging, 2003, 30: 247-258.

Nock B A, Maina T, Behe M, et al. J Nucl Med, 2005, 46: 1727-1736.

Smith C J, Gali H, Sieckman G L, et al. Bioconjugate Chem, 2003, 14: 93-102.

Moustapha M E, Ehrhardt G J, Smith C J, et al. Nucl Med Biol, 2006, 33: 81-89.

Smith C J, Sieckman G L, Owen N K, et al. Anticancer Res, 2003, 23: 63-70.

Smith C J, Sieckman G L, Owen N K, et al. Cancer Res, 2003, 63: 4082-4088.

Garcia-Garayoa E, Ruegg D, Bläuenstein P, et al. Nucl Med Biol, 2006, in press.

Chen J Q, Giblin M F, Wang N N, et al. Nucl Med Biol, 1999, 26: 687-693.

Chen J Q, Cheng Z, Hoffman T J, et al. Cancer Res, 2000, 60: 5649-5658.

Miao Y B, Owen N K, Fisher D R, et al. J Nucl Med, 2005, 46: 121-129.

Dadachova E, Moadel T, Schweitzer A D, et al. Cancer Biotherapy and Radiopharmaceuticals, 2006, 21: 117-129.

Reubi J C. Endocr Rev, 2003, 24: 389-427.

Buchegger F, Bonvin F, Kosinski M, et al. J Nucl Med, 2003, 44: 1649-1654.

Garcia-Garayoa E, Maes V, Blauenstein P, et al. Nucl Med Biol, 2006, 33: 495-503.

Blauenstein P, Garayoa E G, Ruegg D, et al. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19: 181-188.

Ruoslahti E, Pierschbacher M D. Science, 1987, 238: 491-497.

Hynes R O. Cell, 1992, 69: 11-25.

Sivolapenko G B, Skarlos D, Pectasides D, et al. Eur J Nucl Med Mol Imaging, 1998, 10: 1383-1389.

Costopoulos B, Benaki D, Pelecanou M, et al. Inorg Chem, 2004, 43: 5598-5602.

Gestin J F, Loussouarn A, Bardies M, et al. J Nucl Med, 2001, 42: 146-153.

Karacay H, McBride W J, Griffiths G L, et al. Bioconjugate Chem, 2000, 11: 842-854.

Reubi J C, Gugger M, Waser B. Eur J Nucl Med Mol Imaging, 2002, 29: 855-862.

Reubi J C, Waser B. Eur J Nucl Med Mol Imaging, 2003, 30: 781-793

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

LABELLING OF METALLOTHIONEIN WITH ^99mTc

Preparation and biodistribution assessment of ⁶⁸Ga-DKFZ-PSMA-617 for PET prostate cancer imaging

Radio-ligand receptor binding assay in vitro and animal biodistribution in vivo of ⁹⁹Tc^m-N-ethyl-N₂S₂-memantine as a potential NMDA receptor imaging agent

A test device for isotopic γ-ray imaging with CdZnTe detector

Monte-Carlo simulation to determine detector efficiency of plastic scintillating fiber

Related Author

No data

Related Institution

Peking University

General Hospital of P.L. Army

Nuclear Science and Technology Research Institute (NSTRI)

Department of Chemistry, University of Zanjan

Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences

Address：Editorial Office of NST, 2019 Jialuo Road, Jiading, Shanghai 201800, China Postal code：201800
Email：nst@sinap.ac.cn
Technical support is provided by Beijing Founder electronics co., LTD 沪ICP备05005479号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰